Theodore Karrison to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Theodore Karrison has written about Leukemia, Myeloid, Acute.
Connection Strength
0.560
-
Data management and statistical methods used in the analysis of balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and therapy-related acute leukemia: report from an international workshop. Genes Chromosomes Cancer. 2002 Apr; 33(4):346-61.
Score: 0.126
-
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia. Blood Adv. 2020 02 25; 4(4):599-606.
Score: 0.109
-
Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms. Haematologica. 2016 06; 101(6):e232-6.
Score: 0.083
-
Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice. Blood. 2014 Feb 13; 123(7):1069-78.
Score: 0.071
-
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res. 2014 Jan 15; 20(2):490-8.
Score: 0.070
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.047
-
Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A. 2006 Jan 24; 103(4):1030-5.
Score: 0.041
-
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia. Mutat Res. 1989 Apr; 216(2):119-26.
Score: 0.013